Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Interview: Novartis Counts On AS and PsA For Cosentyx Growth

Jun 15 2018

• By Kevin Grogan

Husky — Novartis looks to lead the pack in AS and PsA

Related Content

Wider Than AZ’s PACIFIC – Novartis Has Broad NSCLC Plans For Canakinumab

Nov 15 2017

Novartis Aims Canakinumab At Targeted CV Patients

Nov 13 2017

Novartis Allays Concerns Over Cosentyx Sales Miss

Apr 19 2018

Positive Spondylitis Phase III Brings Lilly's Taltz Closer To Cosentyx's Label

Feb 14 2018

Related Companies

Novartis AG

Eli Lilly and Company

Bausch Health Companies Inc.

LEO Pharma A/S

Johnson & Johnson

Additional Topics

Clinical Trials Companies Immune Disorders Dermatology BioPharmaceutical

More from Immunological

More from Therapeutic Category

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window